Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzer
Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually. Several hundred of these patients are likely to carry known genetic mutations associated with HBOC or LS. Genetic testing for hereditary susc
| Condition(s) | Hereditary Breast and Ovarian Cancer, Lynch Syndrome |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually. Several hundred of these patients are likely to carry known genetic mutations associated with HBOC or LS. Genetic testing for hereditary susceptibility to cancer can prevent many cancer deaths through early identification and engagement in high-risk management care that involves intensive surveillance, chemoprevention and/or prophylactic surgery. However, current rates of genetic testing indicate that many Swiss mutation carriers and their family members do not use cancer genetic services (counseling and/or testing), either due to lack of coordination of care or due to lack of communication about the mutation amon |
| Who can participate | Inclusion Criteria: 1. Carrier of a mutation associated with HBOC or LS 2. Have at least one living blood relative 3. Men and women 4. 18 years old and older 5. Mentally and physically able to provide informed consent 6. Can read and speak German or French or Italian or English 7. Currently living in Switzerland. Exclusion Criteria: 1. Carriers of unclassified variants (VUS) in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2, EPCAM genes 2. Not living in Switzerland 3. Patients who are critically ill and cannot complete the CASCADE survey 4. Participants who are institutionalized (e.g., nursing homes) or incarcerated |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Basel |
| Locations | Fribourg, Canton of Fribourg, Switzerland; Geneva, Canton of Geneva, Switzerland; Delémont, Canton of Jura, Switzerland; Winterthur, Canton of Zurich, Switzerland; Basel, Switzerland; Bellinzona, Switzerland (+3 more sites) |
| Start date | 2017-04-01 |
| NCT ID | NCT03124212 |
| Official listing | https://clinicaltrials.gov/study/NCT03124212 |